Victor L Villemagne

Summary

Affiliation: University of Melbourne
Country: Australia

Publications

  1. doi request reprint Aβ-amyloid and Tau Imaging in Dementia
    Victor L Villemagne
    Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia Electronic address
    Semin Nucl Med 47:75-88. 2017
  2. doi request reprint Neuroimaging biomarkers in Alzheimer's disease and other dementias
    Victor L Villemagne
    Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Victoria 3084, Australia Department of Medicine, University of Melbourne, Austin Health, Victoria 3084, Australia The Florey Institute of Neuroscience and Mental Health, Victoria 3052, Australia Institut National de la Santé et de la Recherche Médicale Inserm, Unite, 1077 Caen, France Electronic address
    Ageing Res Rev 30:4-16. 2016
  3. doi request reprint Amyloid imaging: Past, present and future perspectives
    Victor L Villemagne
    Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia Department of Medicine, The University of Melbourne, Victoria, Australia Electronic address
    Ageing Res Rev 30:95-106. 2016
  4. doi request reprint Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria 3084, Australia Department of Medicine, The University of Melbourne, Austin Health, Victoria 3084, Australia The Florey Institute, The University of Melbourne, Victoria 3010, Australia Electronic address
    Curr Opin Neurobiol 36:43-51. 2016
  5. doi request reprint Tau imaging: early progress and future directions
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Vic, Australia Department of Medicine, The University of Melbourne, Austin Health, Vic, Australia The Florey Institute, The University of Melbourne, Victoria, Australia Electronic address
    Lancet Neurol 14:114-24. 2015
  6. ncbi request reprint Voyage au bout de la nuit: Aβ and tau imaging in dementias
    M D Zwan
    Department of Nuclear Medicine and Centre for PET Austin Health, Heidelberg, Victoria, Australia
    Q J Nucl Med Mol Imaging 58:398-412. 2014
  7. doi request reprint In vivo tau imaging: obstacles and progress
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Vic, Australia The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Vic, Australia Electronic address
    Alzheimers Dement 10:S254-64. 2014
  8. doi request reprint Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing
    Christopher C Rowe
    Austin Health, Department of Nuclear Medicine and Centre for Positron Emission Tomography, Heidelberg, Victoria, Australia
    Ann Neurol 74:905-13. 2013
  9. doi request reprint Decline in cognitive function over 18 months in healthy older adults with high amyloid-β
    Kathryn A Ellis
    Mental Health Research Institute, The University of Melbourne, Parkville, Vic, Australia
    J Alzheimers Dis 34:861-71. 2013
  10. pmc Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia
    Ann Neurol 69:181-92. 2011

Collaborators

Detail Information

Publications68

  1. doi request reprint Aβ-amyloid and Tau Imaging in Dementia
    Victor L Villemagne
    Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia Electronic address
    Semin Nucl Med 47:75-88. 2017
    ....
  2. doi request reprint Neuroimaging biomarkers in Alzheimer's disease and other dementias
    Victor L Villemagne
    Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Victoria 3084, Australia Department of Medicine, University of Melbourne, Austin Health, Victoria 3084, Australia The Florey Institute of Neuroscience and Mental Health, Victoria 3052, Australia Institut National de la Santé et de la Recherche Médicale Inserm, Unite, 1077 Caen, France Electronic address
    Ageing Res Rev 30:4-16. 2016
    ....
  3. doi request reprint Amyloid imaging: Past, present and future perspectives
    Victor L Villemagne
    Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia Department of Medicine, The University of Melbourne, Victoria, Australia Electronic address
    Ageing Res Rev 30:95-106. 2016
    ....
  4. doi request reprint Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria 3084, Australia Department of Medicine, The University of Melbourne, Austin Health, Victoria 3084, Australia The Florey Institute, The University of Melbourne, Victoria 3010, Australia Electronic address
    Curr Opin Neurobiol 36:43-51. 2016
    ....
  5. doi request reprint Tau imaging: early progress and future directions
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Vic, Australia Department of Medicine, The University of Melbourne, Austin Health, Vic, Australia The Florey Institute, The University of Melbourne, Victoria, Australia Electronic address
    Lancet Neurol 14:114-24. 2015
    ..Once validated, selective tau imaging might be useful as a diagnostic, prognostic, and progression biomarker, and a surrogate marker for the monitoring of efficacy and patient recruitment for anti-tau therapeutic trials. ..
  6. ncbi request reprint Voyage au bout de la nuit: Aβ and tau imaging in dementias
    M D Zwan
    Department of Nuclear Medicine and Centre for PET Austin Health, Heidelberg, Victoria, Australia
    Q J Nucl Med Mol Imaging 58:398-412. 2014
    ..Aβ and tau imaging value resides in being not only diagnostic, prognostic or progression markers, but also surrogate markers of disease, crucial for patient recruitment and efficacy evaluation of disease-specific therapies. ..
  7. doi request reprint In vivo tau imaging: obstacles and progress
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Vic, Australia The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Vic, Australia Electronic address
    Alzheimers Dement 10:S254-64. 2014
    ....
  8. doi request reprint Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing
    Christopher C Rowe
    Austin Health, Department of Nuclear Medicine and Centre for Positron Emission Tomography, Heidelberg, Victoria, Australia
    Ann Neurol 74:905-13. 2013
    ..We aimed to determine the prognostic value of β-amyloid imaging, alone and in combination with memory performance, hippocampal atrophy, and apolipoprotein E ε4 status in nondemented, older individuals...
  9. doi request reprint Decline in cognitive function over 18 months in healthy older adults with high amyloid-β
    Kathryn A Ellis
    Mental Health Research Institute, The University of Melbourne, Parkville, Vic, Australia
    J Alzheimers Dis 34:861-71. 2013
    ....
  10. pmc Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia
    Ann Neurol 69:181-92. 2011
    ..Assess Aβ deposition longitudinally and explore its relationship with cognition and disease progression...
  11. doi request reprint Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease
    Yen Ying Lim
    1 The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
    Brain 137:221-31. 2014
    ..Further, these results suggest that grouping amyloid data into at least two categories of abnormality may be useful in determining the disease risk level in non-demented individuals. ..
  12. doi request reprint BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia
    Neurobiol Aging 34:2457-64. 2013
    ..High Aβ levels coupled with Met carriage may be useful prognostic markers of accelerated cognitive decline and hippocampal degeneration in individuals in the preclinical stage of AD. ..
  13. doi request reprint Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging
    Victor L Villemagne
    Mental Health Research Institute, University of Melbourne, Melbourne, Vic, Australia
    Neurodegener Dis 10:161-5. 2012
    ..The noninvasive evaluation of nigrostriatal dopaminergic integrity by PET can provide useful information for the differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)...
  14. doi request reprint Aβ amyloid, cognition, and APOE genotype in healthy older adults
    Yen Ying Lim
    Department of Psychiatry, University of Melbourne, Parkville, Australia
    Alzheimers Dement 9:538-45. 2013
    ..Further, when demographic variables were controlled, the influence of APOE ε4 on the relationship between cerebral Aβ and cognition dissipated...
  15. doi request reprint Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease
    Alan Rembach
    The Mental Health Research Institute, The University of Melbourne, Victoria, Australia Electronic address
    Alzheimers Dement 10:53-61. 2014
    ..A practical biomarker is required to facilitate the preclinical diagnosis of Alzheimer's disease (AD)...
  16. doi request reprint Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease
    Gael Chetelat
    Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Brain 134:798-807. 2011
    ....
  17. doi request reprint Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study
    Kerryn E Pike
    Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Vic, Australia
    Neuropsychologia 49:2384-90. 2011
    ..The finding of gender differences deserves further research to answer definitively the important question of gender susceptibility to adverse cognitive effects from β-amyloid...
  18. doi request reprint In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Hospital, Austin Health, Heidelber, Australia
    Arch Neurol 68:905-12. 2011
    ....
  19. doi request reprint Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease
    Andrew D Watt
    Department of Pathology, The University of Melbourne, Parkville, Melbourne, Victoria, Australia
    J Alzheimers Dis 24:47-59. 2011
    ..Furthermore, the findings indicate that the incorporation of non-amyloid markers into predictive models, function to increase the accuracy of the diagnostic potential of Aβ...
  20. doi request reprint Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Australia
    Neurology 79:1645-52. 2012
    ..Although the APOE ε4 allele is associated with more rapid decline in memory in healthy older adults, the significance of elevated cerebral β-amyloid (Aβ) load for longitudinal changes in cognition is unclear...
  21. doi request reprint Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Nucl Med 52:1210-7. 2011
    ....
  22. doi request reprint Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer's disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS)
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia
    Arch Clin Neuropsychol 28:320-30. 2013
    ..This may potentially be used to inform future estimates of cognitive change in clinical trials...
  23. doi request reprint Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease
    Alan Rembach
    The Mental Health Research Institute, The University of Melbourne, Vic, Australia
    J Alzheimers Dis 34:171-82. 2013
    ..The aim of this study was to determine the diagnostic value of serum copper, CP, and non-CP copper levels in a large cohort of AD subjects...
  24. doi request reprint Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia
    Neuropsychology 27:322-32. 2013
    ..We aimed to determine the extent to which high Aβ amyloid influenced cognitive function in healthy older adults and adults with MCI...
  25. doi request reprint Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative
    Kathryn A Ellis
    Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Kew, Victoria, Australia
    Alzheimers Dement 6:291-6. 2010
    ..Cross-sectional analysis of baseline data is revealing links between cognition, brain amyloid burden, structural brain changes, biomarkers, and lifestyle...
  26. doi request reprint Relationship between atrophy and beta-amyloid deposition in Alzheimer disease
    Gael Chetelat
    Department of Nuclear Medicine and Center for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia
    Ann Neurol 67:317-24. 2010
    ..The present study aims to assess this relationship...
  27. doi request reprint Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β: prodromal Alzheimer's disease?
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Vic, Australia
    J Alzheimers Dis 33:1167-76. 2013
    ....
  28. doi request reprint Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Eur J Nucl Med Mol Imaging 39:983-9. 2012
    ..The purpose of this analysis was to compare data on cortical Aβ deposition in subjects who had undergone both (11)C-PiB (PiB) and (18)F-florbetaben (FBB) PET imaging...
  29. doi request reprint Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease
    Michelle T Fodero-Tavoletti
    Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia
    J Alzheimers Dis 20:49-55. 2010
    ..This approach has the potential to offer complementary information to other diagnostic procedures that elucidate plaque burden...
  30. doi request reprint In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Vic, Australia
    Eur J Pharmacol 617:54-8. 2009
    ..This study suggests that [(18)F]-BF227 is not Abeta-selective. Evaluation of BF227 as a potential biomarker for Parkinson's disease is warranted...
  31. doi request reprint Olfactory deficits and amyloid-β burden in Alzheimer's disease, mild cognitive impairment, and healthy aging: a PiB PET study
    Alex Bahar-Fuchs
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Alzheimers Dis 22:1081-7. 2010
    ..We conclude that AD-related olfactory identification deficits are not directly related to Aβ burden...
  32. doi request reprint Characterization of PiB binding to white matter in Alzheimer disease and other dementias
    Michelle T Fodero-Tavoletti
    Department of Pathology, University of Melbourne, and Department of Nuclear Medicine, Centre for PET, Austin Hospital, Heidelberg, Victoria, Australia
    J Nucl Med 50:198-204. 2009
    ..Although the specificity of PiB for Abeta plaques in gray matter has been well described, the nature of PiB binding to white matter remains unclear. In this study, we characterized the binding of PiB to human white matter homogenates...
  33. doi request reprint Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer's disease
    Gael Chetelat
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Vic, Australia
    Neurodegener Dis 10:141-4. 2012
    ..The development of Aβ ligands for in vivo PET imaging has greatly facilitated the assessment of this question...
  34. doi request reprint A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-beta plaques
    SinChun Lim
    School of Chemistry, The University of Melbourne, Parkville, Victoria, Australia 3010
    Chem Commun (Camb) 46:5437-9. 2010
    ..The complex has the potential to be of use as a copper-64 radiopharmaceutical to assist in the diagnosis of Alzheimer's disease by positron emission tomography...
  35. doi request reprint Larger temporal volume in elderly with high versus low beta-amyloid deposition
    Gael Chetelat
    Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia
    Brain 133:3349-58. 2010
    ..Our complementary analyses tend to support the latter hypotheses. Overall, our findings suggest that the deleterious effects of β-amyloid on cognition may be delayed in those subjects with larger brain (temporal) volume...
  36. doi request reprint Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
    Victor L Villemagne
    Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC 3084, Australia
    Lancet Neurol 12:357-67. 2013
    ..We aimed to use longitudinal data to calculate the rates of amyloid β (Aβ) deposition, cerebral atrophy, and cognitive decline...
  37. doi request reprint 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Victoria, 3010, Australia
    Brain 134:1089-100. 2011
    ..The preclinical examination of THK523 has demonstrated its high affinity and selectivity for tau pathology both in vitro and in vivo, indicating that (18)F-THK523 fulfils ligand criteria for human imaging trials...
  38. doi request reprint The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia
    Mol Neurobiol 38:1-15. 2008
    ..Further longitudinal observations are required to confirm this hypothesis and to better elucidate the role of Abeta deposition in the course of Alzheimer's disease...
  39. doi request reprint Rapid decline in episodic memory in healthy older adults with high amyloid-β
    Yen Ying Lim
    Mental Health Research Institute, The University of Melbourne, Parkville, Vic, Australia
    J Alzheimers Dis 33:675-9. 2013
    ..High Aβ was associated with greater decline in episodic memory measures over 6 months in healthy older adults...
  40. doi request reprint Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease
    Nastasia K H Lim
    Department of Pathology, The University of Melbourne, Parkville VIC, Australia
    J Alzheimers Dis 26:779-86. 2011
    ..16, p < 0.05), but there was no association with PiB. This is the first report of a change in MMP-2 activity in AD plasma and these findings may provide some insight into AD pathogenesis...
  41. doi request reprint APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease
    Yen Ying Lim
    The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA Department of Neurology, Rhode Island Hospital, Providence, RI, USA Electronic address
    Neurobiol Aging 36:1239-44. 2015
    ....
  42. doi request reprint Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    Lancet Neurol 7:129-35. 2008
    ..18)F-BAY94-9172 is an Abeta ligand that, due to the half-life of (18)F, is suitable for clinical use. We thus studied the effectiveness of this ligand in identifying patients with AD...
  43. doi request reprint In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133
    Nobuyuki Okamura
    Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia
    J Nucl Med 51:223-8. 2010
    ..PET provides a noninvasive means to evaluate the functional integrity of the presynaptic monoaminergic system in the living human brain...
  44. pmc Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study
    Yen Ying Lim
    Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
    PLoS ONE 9:e86498. 2014
    ..We aimed to determine whether BDNF Val66Met polymorphism influences changes in memory performance, hippocampal volume, and Aβ accumulation in adults with amnestic mild cognitive impairment (aMCI) and high Aβ...
  45. pmc Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months
    Christine Thai
    Department of Psychology, Royal Melbourne Institute of Technology, Melbourne, Australia
    PLoS ONE 10:e0139082. 2015
    ..These results suggest that Aβ and APOE ε4 interact to increase the rate of cognitive decline in CN older adults and provide further support for the use of Aβ and APOE ε4 as biomarkers of early Alzheimer's disease. ..
  46. doi request reprint Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease
    Rachel F Buckley
    Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia Electronic address
    Alzheimers Dement 12:796-804. 2016
    ....
  47. doi request reprint Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI
    Yen Ying Lim
    The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Vic, Australia Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA
    Arch Clin Neuropsychol 30:49-58. 2015
    ..03, p = .032). This suggests that Aβ accumulation precedes any neurodegeneration or clinical symptoms, and that the relationship between Aβ and cognitive decline is mediated by hippocampal atrophy...
  48. ncbi request reprint Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease
    Kerryn E Pike
    School of Psychology, Psychiatry and Psychological Medicine, Monash University, Melbourne, Australia
    Brain 130:2837-44. 2007
    ..The data also suggests that early intervention trials for AD targeted to non-demented individuals with cerebral Abeta deposition are warranted...
  49. doi request reprint The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies
    Seok Ming Lim
    Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia
    J Nucl Med 50:1638-45. 2009
    ....
  50. pmc Incidence of cerebral microbleeds in preclinical Alzheimer disease
    Paul A Yates
    From the Department of Nuclear Medicine and Centre for PET P A Y, V L V, C C R, Austin Health, Heidelberg The University of Melbourne P A Y, P M D, C S, C C R, Parkville Department of Radiology P M D, P M P, C S, Royal Melbourne Hospital, Parkville National Ageing Research Institute D A, Parkville CSIRO Preventative Health Flagship O S, Parkville Florey Institute of Neuroscience and Mental Health K A E, C L M, V L V, The University of Melbourne, Parkville Academic Unit for Psychiatry of Old Age K A E, D A, Department of Psychiatry, The University of Melbourne, Kew, Victoria Centre of Excellence for Alzheimer s Disease Research and Care R N M, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Australia
    Neurology 82:1266-73. 2014
    ..We sought to determine the incidence and associations of lobar microbleeds (LMBs) in a longitudinal cohort with (11)C-Pittsburgh compound B (PiB) PET imaging...
  51. ncbi request reprint Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B
    Steven Y Ng
    Department of Nuclear Medicine and Centre for Positron Emission Tomography, Austin Health, Melbourne, Australia
    Arch Neurol 64:1140-4. 2007
    ..However, patients presenting with atypical or focal clinical symptoms such as language or visuospatial dysfunction often pose a diagnostic challenge...
  52. doi request reprint Subacute ischemic stroke is associated with focal 11C PiB positron emission tomography retention but not with global neocortical Aβ deposition
    John V Ly
    University of Melbourne, Carlton South, Australia
    Stroke 43:1341-6. 2012
    ..Specifically, we hypothesized that patients with recent ischemic stroke have higher local and neocortical PiB positron emission tomography retention and that this may be associated with major vascular risk factors...
  53. doi request reprint Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease
    Yen Ying Lim
    The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia Electronic address
    Alzheimers Dement 10:743-751.e1. 2014
    ..However, longer prospective studies are required to determine if Aβ-related memory decline continues and whether it is associated with increased rate of disease progression...
  54. ncbi request reprint Advances in structural and molecular neuroimaging in Alzheimer's disease
    Kathryn A Ellis
    Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, Vic, Australia
    Med J Aust 194:S20-3. 2011
    ....
  55. doi request reprint The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI
    Karra D Harrington
    Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia
    Int Psychogeriatr 25:1667-77. 2013
    ..This study aimed to describe the nature and magnitude of the relationship between Aβ amyloid and cognitive performance of individuals without dementia...
  56. doi request reprint High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types
    Victor L Villemagne
    Department of Nuclear Medicine, Centre for Positron Emission Tomography, Austin Health, Heidelberg, Australia
    Arch Neurol 66:1537-44. 2009
    ..Mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes lead to increased Abeta levels before symptoms arise...
  57. doi request reprint Aβ-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease
    Yen Ying Lim
    From The Florey Institute of Neuroscience and Mental Health Y Y L, V L V, C F, C L M, P M, The University of Melbourne, Parkville Centre of Excellence for Alzheimer s Disease Research and Care S M L, T P, S R S, R N M, Edith Cowan University, Joondalup, Australia Department of Psychiatry R H P, Yale University School of Medicine, New Haven, CT Academic Unit for Psychiatry of Old Age D A, St Vincent s Health, The University of Melbourne, Kew National Ageing Research Institute D A, Parkville, Australia Department of Neurology P J S, Warren Alpert Medical School of Brown University, Providence, RI Commonwealth Scientific Industrial Research Organization CSIRO Preventative Health National Research Flagship O S, P B, Australian e Health Research Centre BiaMedIA, Brisbane Departments of Nuclear Medicine and Centre for PET V L V, C C R and Medicine V L V, C C R, Austin Health, Heidelberg Sir James McCusker Alzheimer s Disease Research Unit S M L, T P, Hollywood Private Hospital, Perth Co operative Research Centre for Mental Health S M L, T P, Nutrition Services
    Neurology 86:1635-42. 2016
    ....
  58. doi request reprint Amyloid imaging with PET in early Alzheimer disease diagnosis
    Christopher C Rowe
    Department of Nuclear Medicine, Centre for PET, University of Melbourne, Austin Health, Heidelberg, Victoria 3084, Australia
    Med Clin North Am 97:377-98. 2013
    ..Longitudinal observations are required to elucidate the role of Aβ deposition in the course of Alzheimer disease and provide information needed to fully use the prognostic power of this investigation...
  59. doi request reprint Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study
    Noel G Faux
    The Mental Health Research Institute, The University of Melbourne, Parkville, Vic, Australia
    J Alzheimers Dis 27:909-22. 2011
    ..These findings underscore the association of plasma homocysteine with cognitive deterioration, although not unique to AD, and identified an unexpected abnormality of red cell folate...
  60. pmc Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score
    Yen Ying Lim
    The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
    Alzheimers Dement (Amst) 2:19-26. 2016
    ..We compared the rate of cognitive decline associated with high Aβ (Aβ+) and very high Aβ (Aβ++) in cognitively normal (CN) older adults on three multidomain cognitive composite scores and one single-domain (EM) composite score...
  61. ncbi request reprint Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia
    Yen Ying Lim
    The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, 155 Oak Street, Parkville, Vic, 3052, Australia
    J Mol Neurosci 60:362-370. 2016
    ....
  62. doi request reprint Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL)
    Kathryn A Ellis
    Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne St Vincent s Aged Psychiatry Service, St George s Hospital, Kew, Victoria, Australia
    Int Psychogeriatr 26:543-54. 2014
    ..The first aim was to compute rates of transition from HC to MCI, and MCI to AD. The second aim was to characterize the cognitive profiles of individuals who transitioned to a more severe disease stage compared with those who did not...
  63. doi request reprint Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia
    Christopher C Rowe
    Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
    J Nucl Med 54:880-6. 2013
    ..We compared the cortical and white matter binding of a new (18)F-labeled Aβ tracer, (18)F-AZD4694 (recently renamed NAV4694), with (11)C-PiB in the same subjects...
  64. doi request reprint An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation
    Alan Rembach
    The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria 3052, Australia
    J Neuroimmunol 273:65-71. 2014
    ..In conclusion, the NLR may reflect AD-related inflammatory processes in the periphery, but age and sex are dominant covariates which need to be controlled for in population-based screening...
  65. ncbi request reprint Amyloid imaging in Alzheimer's disease and other dementias
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Melbourne, Victoria, 3010, Australia
    Brain Imaging Behav 3:246-61. 2009
    ....
  66. doi request reprint In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer
    Michelle T Fodero-Tavoletti
    Department of Pathology, The University of Melbourne, Victoria 3010, Australia
    Nucl Med Biol 39:1042-8. 2012
    ..The objective of this study was to determine whether Florbetaben selectively binds to Aβ plaques in postmortem tissue specimens containing mixed pathological hallmarks (i.e., tau and α-synuclein aggregates)...
  67. doi request reprint Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up
    Samantha C Burnham
    From eHealth S C B, CSIRO Health and Biosecurity, Floreat Department of Nuclear Medicine and Centre for PET C C R, Austin Health, Heidelberg Department of Medicine C C R, V L V, Austin Health, University of Melbourne, Heidelberg, Australia Janssen Research and Development D B, Titusville, NJ Mental Health Research Institute A I B, N G F, Academic Unit for Psychiatry of Old Age, Department of Psychiatry D A, and The Florey Institute C L M, V L V, University of Melbourne, Parkville eHealth J D D, CSIRO Health and Biosecurity, Herston Centre of Excellence for Alzheimer s Disease Research and Care S M L, R N M, S R S, School of Medical Sciences, Edith Cowan University, Joondalup School of Biomedical Sciences S M L, Faculty of Health Sciences, Curtin University, Bentley Sir James McCusker Alzheimer s Disease Research Unit Hollywood Private Hospital R N M, S R S, Perth Cogstate P M, Melbourne CSIRO Food and Nutrition Flagship S L M, Melbourne Department of Psychology G S, Macquarie University, Sydney and eHealth W W, CSIRO Health and Biosecurity
    Neurology 87:1093-101. 2016
    ....
  68. doi request reprint Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden
    Alan Rembach
    The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Vic, Australia
    J Alzheimers Dis 40:95-104. 2014
    ..We evaluated the utility of longitudinal measures of plasma amyloid-β (Aβ) as a means to identify pre-symptomatic cognitive decline in Alzheimer's disease (AD) when coupled to neuroimaging and neuropsychological parameters...